Table 4.
Pre and Post-cancer diagnosis functional limitation prevalence overall and by top 5 cancer types
| All (n=5991) | Prostate (n=1741) | Breast (n=1345) | ||||
|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | |
| N (%)a | N (%)a | N (%) | N (%) | N (%) | N (%) | |
| 0–1condition | 200 (10.1) | 239 (14.5) | 62 (8.9) | 66 (11.6) | 41 (11.0) | 35 (10.8) |
| Unclustered conditionsb | 281 (31.6) | 433 (41.3)*** | 67 (15.2) | 98 (21.7)* | 49 (13.9) | 59 (17.9) |
| Musculoskeletal | 699 (41.7) | 856 (48.8)*** | 149 (39.6) | 197 (44.0) | 198 (42.8) | 223 (45.2) |
| Metabolic | 229 (15.2) | 393 (25.0)*** | 62 (24.3) | 97 (34.4)* | 77 (37.0) | 92 (35.7) |
| CVDc | 160 (43.8) | 248 (54.2)** | 45 (42.5) | 65 (51.6) | 26 (55.3) | 38 (58.5) |
| MDDrd+GIe+Pulmonary | 344 (51.7) | 477 (58.0)* | 28 (50.0) | 65 (63.1) | 42 (50.0) | 105 (52.4) |
| ≥2 clusters | 195 (56.0) | 310 (59.9) | 72 (45.0) | 104 (52.3) | 81 (11.7) | 106 (54.6) |
| CRC (n=904) | Genitourinary (n=646) | Lung (n=593) | ||||
| Pre | Post | Pre | Post | Pre | Post | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| 0–1 condition | 34 (11.9) | 38 (15.8)*** | 21 (11.5) | 29 (19.5)* | 18 (11.3) | 31 (25.4)** |
| Unclustered conditionsb | 35 (16.8) | 67 (27.5)** | 17 (10.3) | 43 (23.8)*** | 18 (11.5) | 61 (34.9)*** |
| Musculoskeletal | 114 (42.2) | 117 (49.2) | 85 (42.9) | 109 (54.0)* | 76 (43.9) | 98 (62.4)*** |
| Metabolic | 53 (33.8) | 82 (46.9)* | 37 (32.2) | 55 (44.7)* | 27 (38.6) | 58 (58.0)* |
| CVDc | 32 (46.4) | 48 (55.8) | 22 (36.1) | 35 (49.3) | 19 (42.2) | 35 (61.4) |
| MDDrd+GIe+Pulmonary | 31 (65.9) | 47 (64.4) | 25 (62.5) | 28 (53.9) | 47 (60.3) | 83 (64.8) |
| ≥2 clusters | 62 (56.9) | 80 (65.6) | 48 (50.0) | 64 (58.7) | 46 (29.0) | 72 (66.1) |
a
Percentages represent % of those with functional limitations within each cluster;
*
p<0.05;
**
p<0.01;
***
p<0.001 for chi-square test of differences from pre- to post-cancer diagnosis;
b
Individuals with ≥2 conditions and were considered “un-clustered”.
c
Cardiovascular disease cluster.
d
Major Depressive Disorder risk.
e
Gastrointestinal conditions.